Document:

EX-10.1

 Exhibit 10.1 
  

			
	 

		Orexigen Therapeutics, Inc.
		3344 North Torrey Pines Court
		Suite 200
		La Jolla, CA 92037
		Phone: 858-875-8600
		Fax 858-875-8650
		
			www.orexigen.com

  
 June 25, 2015

 Heather D. Turner 
 c/o Orexigen Therapeutics, Inc. 

3344 N. Torrey Pines Court, Suite 200 
 La Jolla, CA 92037 

 

	RE:	Separation and Consulting Agreement 

 Dear Heather: 

This letter sets forth the terms of the separation and consulting agreement (this “Agreement”) that Orexigen Therapeutics, Inc. (the
“Company”) is offering to you in connection with your voluntary resignation as an officer and employee of the Company. 

1. Separation Date. You agree and acknowledge that your last day of employment with the Company and your employment resignation date
will be effective June 25, 2015 (the “Separation Date”). As of the Separation Date, you will no longer be employed as the Company’s Senior Vice-President, General Counsel and Secretary, and you will no longer hold
any other employment or officer positions with the Company. You further acknowledge and agree that the circumstances of your employment resignation do not qualify as an “Involuntary Termination Without Cause” or a “Constructive
Termination During a Change in Control Period” as defined in your February 22, 2010 Amended and Restated Employment Agreement with the Company, as amended on February 15, 2013 (together, the “Employment
Agreement”), or otherwise entitle you to any severance benefits. 
 2. Accrued Salary and Vacation. No later than the
Separation Date, the Company will pay you all accrued salary, and all accrued and unused vacation earned through the Separation Date, subject to standard payroll deductions and withholdings. You will receive these payments regardless of whether you
enter into this Agreement. 
 3. Expenses. You should submit, within thirty (30) days after the Separation Date, expense reports
to the Company seeking reimbursement for any business expenses incurred through the Separation Date. The Company will reimburse you for these business expenses, pursuant to its standard policies and practices. Please submit your expense report to:
Orexigen Therapeutics, Inc.; Attn: Finance, 3344 N. Torrey Pines Court, Suite 200, La Jolla, CA 92037. 
 4. Termination Benefits.
Although the Company is not otherwise obligated to do so, if you timely sign, date and return this fully executed Agreement to the Company no later 

 Heather D. Turner 

June 25, 2015 
  Page
 2
 
  

 
than twenty-one (21) calendar days following the date of this Agreement and this Agreement, and the release of claims set forth in Section 14 below, becomes effective on the eighth day
following your timely execution of this Agreement (the “Effective Date”), the Company will provide you with the following termination benefits (the “Termination Benefits”): 

(a) Continued Eligibility for 2015 Bonus. You will remain eligible for a pro-rated annual bonus for calendar year 2015 (the
“Bonus”), which will be determined within the sole discretion of the Company’s Board of Directors (the “Board”), or an authorized committee or officer of the Company, if so delegated by the Board.
If the Board (or authorized committee or officer) approves a Bonus for you, such Bonus will be subject to standard payroll deductions and withholdings, and will be paid to you during the 2016 calendar year at the same time that 2015 bonuses are paid
to the Company’s other eligible executive employees (but in no event will the Bonus be paid to you later than March 15, 2016). 

(b) Consulting Agreement. The Company will agree to retain you, and you will agree to make yourself available to perform services as a
consultant under the terms of the Consulting Agreement attached hereto as Exhibit B. You must sign and return the Consulting Agreement no later than the date that you return this fully signed Agreement. 

5. Health Insurance. To the extent provided by the federal COBRA law or, if applicable, state insurance laws (collectively,
“COBRA”), and by the Company’s current group health insurance policies, you will be eligible to continue your group health insurance benefits after the Separation Date. Later, you may be able to convert to an individual
policy through the provider of the Company’s health insurance, if you wish, at your own expense. You will be provided with a separate notice more specifically describing your rights and obligations to continuing health insurance coverage under
COBRA on or after the Separation Date. 
 6. Equity. 

(a) Although the terms of each of your outstanding stock options, as set forth on Exhibit A hereto (the
“Options”), provide that the Options will expire and cease to be exercisable three months following the termination of your services, you acknowledge and agree that the Options will expire and cease to be exercisable on
March 31, 2016 (the “Expiration Date”) and that, subject to Section 6(b), you may exercise on or before the Expiration Date any of the Options that were vested and exercisable as of the Separation Date. 

(b) You acknowledge and agree that from the Separation Date and continuing through the Expiration Date, you will continue to be subject
to all applicable trading blackout periods and employee policies relating to the trading, sale or purchase of any shares of the Company’s common stock, including but not limited to any shares you acquire, or have acquired, upon your exercise of
your Options prior to the Expiration Date, including that you will be required to secure permission from the Company’s Chief Financial Officer or General Counsel before initiating any such trade, sale or purchase. Any failure to comply with the
terms of this Agreement will result in the immediate expiration of your Options. 

 Heather D. Turner 

June 25, 2015 
  Page
 3
 
  

 (c) Notwithstanding anything to the contrary in this Agreement, you acknowledge and
agree that any portions of the Options that are unvested and unexercisable as of the Separation Date, will not become vested or exercisable, and you will receive no additional vesting of such Options from and after the Separation Date, and all such
portions of such Options will immediately expire and terminate as of such Separation Date. 
 7. No Other Compensation or Benefits.
You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation, bonus, severance, or benefits before or after the Separation Date, with the sole exception
of any benefit the right to which has vested as of the Separation Date under the express terms of a Company benefit plan. 
 8. Return of
Company Property. You agree to immediately return to the Company all Company documents (and all copies thereof) and other Company property which you have in your possession or control, including but not limited to any materials of any kind which
contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part). You also agree to immediately make a diligent search to locate any such documents, property and information. In
addition, if you have used any personally owned computer, server, e-mail system, mobile phone, or portable electronic device (e.g., BlackBerry, iPhone or iPad) (collectively, “Personal Systems”) to receive, store,
prepare or transmit any Company confidential or proprietary data, materials or information, then on or before the fifth day following the Separation Date, or earlier if requested, you will provide the Company with a computer-useable copy of all such
information and then permanently delete and expunge all such Company confidential or proprietary information from such Personal Systems without retaining any copy or reproduction in any form. You agree to provide the Company access to your Personal
Systems, if requested, for the purpose of verifying that the required copying and/or deletion is completed. The Company will provide you with access to its confidential and proprietary information or materials to the extent needed for you to perform
your consulting services. 
 9. Proprietary Information Obligations. You agree to refrain from any use or disclosure of the
Company’s confidential or proprietary information or materials. Additionally, you reaffirm your obligation to comply with the Proprietary Information and Inventions Assignment Agreement (the “Proprietary Information and Inventions
Assignment Agreement”) you previously signed (attached hereto as Exhibit C). 
 10. Mutual Nondisparagement.
You agree not to disparage the Company, and the Company’s officers, directors, employees, shareholders, investors and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation, and the
Company agrees to direct its officers and directors not to disparage you in any manner likely to 

 Heather D. Turner 

June 25, 2015 
  Page
 4
 
  

 
be harmful to your business, business reputation or personal reputation; provided that the parties may respond accurately and fully to any question, inquiry or request for information when
required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation. 

11. Confidentiality. The provisions of this Agreement will be held in strictest confidence by you and the Company and will not be
publicized or disclosed in any manner whatsoever; provided, however, that: (a) you may disclose this Agreement to your immediate family; (b) the parties may disclose this Agreement in confidence to their respective attorneys,
accountants, auditors, tax preparers, and financial advisors; (c) the Company may disclose this Agreement as necessary to fulfill standard or legally required corporate reporting or disclosure requirements; and (d) the parties may disclose
this Agreement insofar as such disclosure may be necessary to enforce its terms or as otherwise required by law. In particular, and without limitation, you agree not to disclose the terms of this Agreement to any current or former Company employee
or affiliate. 
 12. Cooperation. You agree to voluntarily cooperate with the Company, if you have knowledge of facts relevant to any
threatened or pending claim, investigation, audit or litigation against or by the Company, by making yourself reasonably available without further compensation (except pursuant to the Consulting Agreement, and other than your preapproved, reasonable
and documented expenses) for interviews with the Company or its legal counsel, for preparing for and providing deposition testimony, and for preparing for and providing trial testimony. 

13. No Admissions. Nothing contained in this Agreement shall be construed as an admission by you or the Company of any liability,
obligation, wrongdoing or violation of law. 
 14. Release of Claims.  

(a) General Release. In exchange for the consideration provided to you under this Agreement to which you would not otherwise be
entitled, you hereby generally and completely release the Company and its current and former directors, officers, employees, shareholders, investors, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers,
affiliates, and assigns (collectively, the “Released Parties”) of and from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or
omissions occurring prior to or on the date you sign this Agreement (collectively, the “Released Claims”). 
 (b)
Scope of Release. The Released Claims include, but are not limited to: (i) all claims arising out of or in any way related to your employment with the Company, or the termination of that employment; (ii) all claims related to your
compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the

 Heather D. Turner 

June 25, 2015 
  Page
 5
 
  

 
Company; (iii) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing (including but not limited to all claims for
severance benefits under your Employment Agreement); (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v) all federal, state, and local statutory claims,
including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990 (as amended), the federal Family
and Medical Leave Act (as amended) (“FMLA”), the federal Age Discrimination in Employment Act of 1967 (as amended) (the “ADEA”), the California Labor Code (as amended), the California Family Rights Act
(“CFRA”), and the California Fair Employment and Housing Act (as amended). 
 (c) Excluded Claims.
Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”): (i) any rights or claims for indemnification you may have pursuant to any written indemnification
agreement with the Company to which you are a party, the charter, bylaws, or operating agreements of the Company, or under applicable law; (ii) any rights which are not waivable as a matter of law; and (iii) any claims for breach of this
Agreement. In addition, nothing in this Agreement prevents you from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, the California Department of Fair
Employment and Housing, or any other government agency, except that you acknowledge and agree that you are hereby waiving your right to any monetary benefits in connection with any such claim, charge or proceeding. You hereby represent and warrant
that, other than the Excluded Claims, you are not aware of any claims you have or might have against any of the Released Parties that are not included in the Released Claims. 

(d) ADEA Waiver. You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you may have under the ADEA
(the “ADEA Waiver”), and that the consideration given for this ADEA Waiver is in addition to anything of value to which you are already entitled. You further acknowledge that you have been advised, as required by the ADEA,
that: (i) your ADEA Waiver does not apply to any rights or claims that may arise after the date that you sign this Agreement; (ii) you should consult with an attorney prior to signing this Agreement (although you may choose
voluntarily not to do so); (iii) you have twenty-one (21) calendar days to consider this Agreement (although you may choose voluntarily to sign it earlier); (iv) you have seven (7) calendar days following the date you sign this
Agreement to revoke the ADEA Waiver (by providing written notice of your revocation to the Company); and (v) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the Effective Date,
provided that you do not revoke it prior to such date. 
 (e) Section 1542 Waiver. In giving the releases set forth in this
Agreement, which include claims which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code which reads as follows:  

 Heather D. Turner 

June 25, 2015 
  Page
 6
 
  

 
“A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or
her must have materially affected his or her settlement with the debtor.” You hereby expressly waive and relinquish all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect
to the releases granted herein, including but not limited to the release of unknown and unsuspected claims granted in this Agreement. 

15. Representations. You hereby represent that you have been paid all compensation owed for all time worked, you have received all the
leave and leave benefits and protections for which you are eligible pursuant to the FMLA, CFRA or any applicable laws or Company policies, and you have not suffered any work-related injury or illness for which you have not already filed a
workers’ compensation claim. 
 16. Miscellaneous. This Agreement, along with Exhibits A, B, and C constitutes the complete,
final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein,
and it supersedes any other such promises, warranties or representations (including but not limited to those in the Employment Agreement). This Agreement may not be modified or amended except in a written agreement signed by both you and a duly
authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, and their heirs, successors and assigns. If
any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question shall be deemed modified so as to be rendered
enforceable in a manner consistent with the intent of the parties, insofar as possible under applicable law. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or
rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. This Agreement shall be deemed to have been entered into, and shall be construed and enforced, in accordance with the laws of
the State of California without regard to conflicts of law principles. This Agreement may be executed in counterparts, each of which shall be deemed to be part of one original, and facsimile signatures and signatures transmitted by PDF shall be
equivalent to original signatures. 
 If this Agreement is acceptable to you, please sign and date it below within twenty-one (21) calendar days of
your receipt of this Agreement. If you do not sign and return it to the Company within the aforementioned timeframe, the Company’s offer to enter into this Agreement will expire (including the offer to enter into the Consulting Agreement). 

 Heather D. Turner 

June 25, 2015 
  Page
 7
 
  

 We wish you the best in your future endeavors. 

Sincerely, 
 OREXIGEN
THERAPEUTICS, INC. 
  

			
	By:		 /s/ Michael A. Narachi

			Michael A. Narachi
			President & Chief Executive Officer

 Exhibit A – Option Grants 

Exhibit B – Consulting Agreement 
 Exhibit C –
Proprietary Information and Inventions Agreement 
 AGREED: 

 

					
	 /s/ Heather D. Turner
				 6/25/15

	Heather D. Turner				Date

 Heather D. Turner 

June 25, 2015 
  Page
 8
 
  

 EXHIBIT A 

OPTION GRANTS 
  

													
	 	  	Number of Shares
Subject to
Option Grant	 	  	Number of
Unvested Shares
Underlying Option
as of
Separation Date	 	  	Number of Vested and
Outstanding Shares
Underlying Option as
of
Separation Date	 
	 Stock Option granted February 3, 2015
	  	 	153,050	  	  	 	140,296	  	  	 	12,754	  
	 Stock Option granted February 7, 2014
	  	 	205,000	  	  	 	136,667	  	  	 	68,333	  
	 Stock Option granted February 15, 2013
	  	 	240,000	  	  	 	100,000	  	  	 	140,000	  
	 Stock Option granted January 25, 2012
	  	 	350,000	  	  	 	51,043	  	  	 	298,957	  
	 Stock Option granted July 25, 2011
	  	 	1,093,396	  	  	 	22,785	  	  	 	634,147	  

 EXHIBIT B 

Consulting Agreement 

 EXHIBIT C 

Proprietary Information and Inventions AgreementEX-4.1

 Exhibit 4.1 

SUPPLEMENTAL INDENTURE 

DATED AS OF JUNE 25, 2015 

to 
 INDENTURE 

dated as of December 12, 2014 

among 
 COTT BEVERAGES
INC., 
 as Issuer 

THE GUARANTORS NAMED THEREIN 

as Guarantors 
 and

 WELLS FARGO BANK, NATIONAL ASSOCIATION 

as Trustee 

 THIS SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of June 25,
2015, is by and among Cott Beverages Inc., a Georgia corporation (the “Issuer”), Cott Corporation, a Canadian corporation (the “Company”), the other Guarantors (as defined in the Indenture referred to herein) and Wells Fargo
Bank, National Association, a national banking association, as trustee under the Indenture referred to below (the “Trustee”). 

W I T N E S S E T H 

WHEREAS, the Issuer, the Company and the other Guarantors have heretofore executed and delivered to the Trustee an indenture (as amended,
restated, supplemented or otherwise modified, the “Indenture”), dated as of December 12, 2014, providing for the issuance of 6.75% Senior Notes due 2020 (the “Notes”); 

WHEREAS, pursuant to Sections 9.1(5) and 9.5 of the Indenture, the Issuer, the Company, the other Guarantors and the Trustee may
(i) amend or supplement any Note Documents to make any change that does not adversely affect the rights of any Holder in any material respect without the consent of the Holders and (ii) execute and deliver this Supplemental Indenture
without the consent of Holders; and 
 WHEREAS, the Issuer currently intends to take the position that this Supplemental Indenture has not
resulted in a material modification of the Notes for purposes of Sections 1471 through 1474 of the Code (“FATCA”). For the avoidance of doubt, the Issuer shall give the Trustee prompt written notice if it concludes that any material
modification of the Notes has been deemed to occur for FATCA purposes. The Trustee shall assume that no material modification for FATCA purposes has occurred regarding the Notes, unless the Trustee receives written notice of such modification from
the Issuer; 
 NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the Issuer, the Company, the other Guarantors and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 

1. CAPITALIZED TERMS. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture. 

2. AMENDMENT TO SECTION 10.2(b) OF THE INDENTURE. The Indenture is hereby amended by deleting Section 10.2(b) in its entirety and
replacing it with the following: 
 “(b) Any Guarantee of a Guarantor shall terminate upon: 

(1) (A) a sale or other disposition (including by way of consolidation or merger) of the Capital Stock of such Guarantor
(after which such Guarantor is no longer a Restricted Subsidiary) or (B) the sale or disposition of all or substantially all the assets of the Guarantor (other than to the Company or a Restricted Subsidiary) otherwise permitted by this
Indenture; 
 (2) the designation in accordance with this Indenture of the Guarantor as an Unrestricted Subsidiary or the
occurrence of any event after which the Guarantor is no longer a Restricted Subsidiary; 

  
 2 

 (3) defeasance or discharge of the Notes pursuant to
Article VIII or Article XI; 
 (4) to the extent that such Guarantor is not an Immaterial
Subsidiary solely due to the operation of clause (i) of the definition of “Immaterial Subsidiary,” upon the release of the guarantee referred to in such clause; or 

(5) to the extent such Guarantor is also a guarantor or borrower under the New Credit Agreement and, at the time of release of
its Guarantee, (x) has been released from its guarantee of, and all pledges and security, if any, granted in connection with the New Credit Agreement, (y) does not Guarantee any Indebtedness of the Company or any of the other Guarantors,
and (z) there is no Indebtedness outstanding that was Incurred by such Guarantor under Section 3.2(a) in its status as a Guarantor; 

provided, however, that the Guarantee of the Company may only be released under this Section 10.2(b) pursuant to
clause (b)(3) immediately above.” 
 3. NO RECOURSE AGAINST OTHERS. No director, officer, employee, incorporator, stockholder, partner
or member of the Issuer, the Company or any other Guarantor, as such, will have any liability for any obligations of the Issuer, the Company or the other Guarantors under the Notes, the Indenture, this Supplemental Indenture, the Note Guarantees or
for any claim based on, in respect of, or by reason of, such obligations or there creation. Each Holder of Notes accepting a Note waivers and releases all such liability. The waiver and release are part of the consideration for issuance of the
Notes. The waiver may not be effective to waive liabilities under the federal securities laws. 
 4. NEW YORK LAW TO GOVERN. THE INTERNAL
LAW OF THE STATE OF NEW YORK SHALL GOVERN AND BE USED TO CONSTRUE THIS SUPPLEMENTAL INDENTURE WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED
THEREBY. 
 5. COUNTERPARTS. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an
original, but all of them together represent the same agreement. 
 6. EFFECT OF HEADINGS. The Section headings herein are for convenience
only and shall not affect the construction hereof. 
 7. THE TRUSTEE. The Trustee shall not be responsible in any manner whatsoever for or
in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Issuer, the Company and the other Guarantors. 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date first above written. 
  

			
	COTT BEVERAGES INC.
		
	By:		 /s/ Jerry Fowden

	Name:		Jerry Fowden
	Title:		Chief Executive Officer
	
	156775 CANADA INC.
	2011438 ONTARIO LIMITED
	804340 ONTARIO LIMITED
	967979 ONTARIO LIMITED
	COTT CORPORATION
	COTT HOLDINGS INC.
	COTT VENDING INC.
	 INTERIM BCB, LLC,
 as
Guarantors

		
	By:		 /s/ Jerry Fowden

	Name:		Jerry Fowden
	Title:		Chief Executive Officer

 
			
	AIMIA FOODS EBT COMPANY LIMITED
	AIMIA FOODS GROUP LIMITED
	AIMIA FOODS HOLDINGS LIMITED
	AIMIA FOODS LIMITED
	CALYPSO SOFT DRINKS LIMITED
	COOKE BROS HOLDINGS LIMITED
	COOKE BROS. (TATTENHALL), LIMITED
	COTT DEVELOPMENTS LIMITED
	COTT VENTURES LIMITED
	COTT VENTURES UK LIMITED
	MR FREEZE (EUROPE) LIMITED
	STOCKPACK LIMITED
	 TT CALCO LIMITED,
 as
Guarantors

		
	By:		 /s/ Jason Ausher

	Name:		Jason Ausher
	Title:		Director
	
	DS SERVICES OF AMERICA, INC.
	DS SERVICES HOLDINGS, INC.
	DSS GROUP, INC.
	 DS CUSTOMER CARE, LLC,
 as
Guarantors

		
	By:		 /s/ Jason Ausher

	Name:		Jason Ausher
	Title:		Treasurer

  
 5 

 
			
	CAROLINE LLC
	CLIFFSTAR LLC
	COTT ACQUISITION LLC
	COTT U.S. ACQUISITION LLC
	 STAR REAL PROPERTY LLC,
 as
Guarantors

		
	By:		 /s/ Marni Morgan Poe

	Name:		Marni Morgan Poe
	Title:		Vice President
	
	 COTT INVESTMENT, L.L.C.,
 as a
Guarantor

		
	By:		 /s/ Marni Morgan Poe

	Name:		Marni Morgan Poe
	Title:		Secretary

  
 6 

 
			
	COTT (NELSON) LIMITED
	COTT BEVERAGES LIMITED
	COTT EUROPE TRADING LIMITED
	COTT LIMITED
	COTT NELSON (HOLDINGS) LIMITED
	COTT PRIVATE LABEL LIMITED
	 COTT RETAIL BRANDS LIMITED,
 as
Guarantors

		
	By:		 /s/ Gregory Leiter

	Name:		Gregory Leiter
	Title:		Director

  
 7 

 
			
	COTT USA FINANCE LLC.
	as a Guarantor
		
	By:		 /s/ Ceaser Gonzalez

	Name:		Ceaser Gonzalez
	Title:		Director Manager

  
 8 

 
			
	COTT LUXEMBOURG S.A.R.L.
	as a Guarantor
		
	By:		 /s/ Jeremy Hoyle

	Name:		Jeremy Hoyle
	Title:		Class A Manager

  
 9 

 
			
	COTT ACQUISITION LIMITED
	COTT UK ACQUISITION LIMITED,
	as Guarantors
		
	By:		 /s/ Jay Wells

	Name:		Jay Wells
	Title:		Director

  
 10 

 
			
	WELLS FARGO BANK, NATIONAL ASSOCIATION,
	as Trustee
		
	By:		 /s/ Maddy Hughes

	Name:		Maddy Hughes
	Title:		Vice President

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]